The Manufacturers Life Insurance Company Takes $27.11 Million Position in Moderna, Inc. $MRNA

The Manufacturers Life Insurance Company acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 387,074 shares of the company’s stock, valued at approximately $27,107,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Moderna during the first quarter valued at approximately $415,000. NewEdge Advisors LLC increased its stake in shares of Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after purchasing an additional 10,185 shares in the last quarter. United Services Automobile Association purchased a new stake in shares of Moderna in the first quarter worth $230,000. Focus Partners Wealth raised its position in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after purchasing an additional 8,706 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Moderna by 5.2% during the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after purchasing an additional 2,410 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company’s stock.

Moderna Stock Down 4.6%

MRNA opened at $142.77 on Friday. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $75.62 and a two-hundred day simple moving average of $59.17. The company has a market capitalization of $57.00 billion, a PE ratio of -17.87 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the business earned ($2.13) earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, August 19th. William Blair raised Moderna from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 19th. JPMorgan Chase & Co. boosted their price objective on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Finally, Wolfe Research upgraded Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $74.31.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.